Triterpenoid saponin flaccidoside II from Anemone flaccida triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors via the MAPK-HO-1 pathway

Lin-tao Han1
Yin Fang1
Yan Cao2
Feng-hua Wu1
E Liu2
Guo-yan Mo2
Fang Huang1
1China Key Laboratory of TCM Resource and Prescription, Ministry of Education, 2Department of Pharmacy, Hubei University of Chinese Medicine, Wuhan, Hubei, People’s Republic of China

Abstract: Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive soft tissue neoplasms that are extremely rare and are frequently associated with neurofibromatosis type 1 patients. MPNSTs are typically fatal, and there is no effective treatment so far. In our previous study, we showed that flaccidoside II, one of the triterpenoid saponins isolated from Anemone flaccida Fr. Schmidt, has antitumor potential by inducing apoptosis. In the present study, we found that flaccidoside II inhibits proliferation and facilitates apoptosis in MPNST cell lines ST88-14 and S462. Furthermore, this study provides a mechanism by which the downregulation of heme oxygenase-1 via extracellular signal-regulated kinase-1/2 and p38 mitogen-activated protein kinase pathways is involved in the apoptotic role of flaccidoside II. This study suggested the potential of flaccidoside II as a novel pharmacotherapeutic approach for MPNSTs.

Keywords: flaccidoside II, malignant peripheral nerve sheath tumors, apoptosis, MAPK, HO-1

Introduction

Neurofibromatosis (NF) is one of the most common human single-gene disorders, which clinically and genetically predisposes individuals to develop various benign and malignant tumors in the central and peripheral nervous systems, particularly in the brain.1,2 NF is an autosomal dominant disorder, which results from mutations in either of the two tumor suppressor genes NF1 (neurofibromin) and NF2 (merlin). NF1 affects one in 3,500 individuals around the world, regardless of ethnicity and sex,3 and the most common occurrences are benign neurofibromas in NF1 patients, which include two subgroups: plexiform and dermal.4,5 Plexiform neurofibromas can progress to malignant sarcomas known as malignant peripheral nerve sheath tumors (MPNSTs), which are highly aggressive, resistant to conventional chemotherapy or surgical resection, and typically fatal, and are therefore a leading cause of mortality in NF1 patients.6,7 The absence of effective treatment for MPNSTs and NF1 unfolds the significance of understanding NF1 tumor development and seeking for effective therapeutic tools. Since the progress of MPNST is associated with additional genetic changes in oncogenes or loss of tumor suppressors, genetic modeling alongside NF1 has been considered to prevent MPNST development,8 although eventual resistance or tumor burden hinders its efficacy,9 new strategies for inhibition of both proliferation and survival are in need.
The genus *Anemone* is widely distributed around the world, and ~1/3 species of *Anemone* are found in the People’s Republic of China, which have been shown as valuable sources of diverse saponin compounds with useful biological properties. Anemone flaccida is widely used as Chinese folk medicine, and triterpenoid saponins, the main effective and characteristic ingredients of this genus, possess extensive biological activities, such as antimutant, antioxidative, and antibacterial properties. Several triterpenoid saponins were isolated, and their bioactivities have been reported. In our previous work, we have isolated five triterpenoid saponins from *A. flaccida* Fr. Schmidt: glycoside St-I4a (1), glycoside St-J (2), anhuieroside E (3), hederasaponin B (4), and flaccidoside II (5), which have shown antimutant effects by inducing apoptosis via cyclooxygenase-2/prostaglandin E2 (COX-2/PGE2) pathway. Accumulated evidence suggests that saponins have potential therapeutic effects on central nervous system disorders, such as stroke, Alzheimer’s disease, and Parkinson’s disease, while phytotherapy did not receive widespread attention. Here, we investigated the effect of triterpenoid saponin from *A. flaccida* on NF-related MPNSTs, and we found that flaccidoside II inhibited proliferation and facilitated apoptosis significantly in MPNST cell lines ST88-14 and S462.

The progress toward understanding the cellular and molecular alterations that are mediated by flaccidoside II may help in developing effective preventative and therapeutic strategies. The mammalian family of mitogen-activated protein kinases (MAPKs), including extracellular signal-regulated kinase (ERK), p38 MAPK, and c-Jun N-terminal kinase (JNK), are evolutionarily conserved kinase modules that link extracellular signals to the machinery that controls fundamental cellular processes, including growth, proliferation, differentiation, and apoptosis, which play key roles in several steps of tumorigenesis, including cancer cell proliferation, migration, and invasion. Here, we assessed the effects of flaccidoside II on MAPK signaling pathways in our system and found that certain underlying pathways are involved in the antiapoptotic role of flaccidoside II.

We also investigated the role of flaccidoside II on heme oxygenase (HO)-1 and its antiapoptotic effect on MPNSTs. HO-1 is the inducible isofrom of the first and rate-limiting enzyme of heme degradation. It has been reported that HO-1 not only protects against oxidative stress but also has potent anti-inflammatory functions. Furthermore, HO-1 also exerts facilitating effects on angiogenesis and on the proliferation of sarcoma and hepatoma cells in vivo. These findings suggest that the cytoprotective effect of HO-1 can modify the endogenous balance between apoptosis and proliferation toward an antiapoptotic and proproliferative status, which are relevant to oncogenesis, maintenance, and resistance to chemotherapy. In contrast, pharmacological agents that downregulate HO activity or HO-1 expression may become powerful tools for preventing the onset or progression of cancers and sensitize them to anticancer therapies. Coincidentally, we found in our experiments that flaccidoside II reduced the expression level and the activity of HO-1 in MPNST cell lines. Interestingly, our work also suggested that the roles of flaccidoside II on MAPK pathway might consequently affect the downstream HO-1, which ultimately triggers apoptosis in MPNST cell lines.

Collectively, the protective role of flaccidoside II on MPNSTs is revealed in this study. To our knowledge, this is the first study to report that flaccidoside II has antitumor capacity in the nervous system, which might represent a new insight for MPNST patient therapy and also reveal that the MAPK-HO-1 pathway is involved in the underlying mechanisms. This study might provide us clues for the development of new therapeutic drugs for NF1-associated MPNSTs.

**Materials and methods**

**Cells and reagents**

The NF1-deficient human MPNST cell lines ST88-14 and S462 were cultured in Dulbecco’s Modified Eagle’s Medium (10% fetal bovine serum, 1% penicillin–streptomycin, 1% L-glutamine, and 1% sodium pyruvate) and incubated at 37°C in a humidified atmosphere containing 10% carbon dioxide. No ethical committee approval was required for this set of experiments because the experiments were performed on commercially available cell lines. Dulbecco’s Modified Eagle’s Medium, fetal bovine serum, and tissue culture reagents were obtained from Thermo Fisher Scientific, Waltham, MA, USA. The following antibodies were used: anti-HO-1 (Epitomics, Burlingame, CA, USA), antiphospho-p38 (Cell Signaling Technology, Beverly, MA, USA), antiphospho-ERK-1/2 (Cell Signaling Technology), antiphospho-JNK (Santa Cruz Biotechnology Inc., Dallas, TX, USA), anti-p38 (Cell Signaling Technology), anti-ERK-1/2 (Cell Signaling Technology), anti-JNK (Santa Cruz Biotechnology Inc.), and anti-GAPDH (Abcam, Cambridge, MA, USA). All other chemicals and reagents were of analytical grade.

**Cell proliferation**

MPNST cell lines ST88-14 and S462 were plated onto 96-well plates at a concentration of 10,000 cells/well in serum-containing growth medium. Viability of MPNST cell lines treated with triterpenoid saponin was assessed using CellTiter 96® Aqueous Non-Radioactive
Cell Proliferation Assay (Promega Corporation, Fitchburg, WI, USA). After 24-hour incubation, cells were treated with carrier alone (0.1% dimethyl sulfoxide [DMSO]), or flaccidoside II at the following gradient concentrations: 40.0 μmol L⁻¹, 20.0 μmol L⁻¹, 10.0 μmol L⁻¹, 5.0 μmol L⁻¹, and 2.50 μmol L⁻¹. After incubation for 24 hours or 48 hours, the medium was carefully removed, replaced with fresh medium, 20 μL of 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) was added to each well, and incubated at 37°C for 2 hours. The amount of proliferation was quantified by MTS assay using Cell titer 96 proliferation kit (Promega Corporation), and absorbance at 490 nm was read in a Spectramax M2 plate reader ( Molecular Devices LLC, Sunnyvale, CA, USA) at the designated time points. The percentage of viable cells at each condition was calculated by dividing the absorbance (A490) of treated cells by that of control cells. The half maximal inhibitory concentration (IC₅₀) was determined from the graph of cell viability (%) vs concentrations. Each experiment was performed in quadruplicate and repeated three times independently.

Apoptosis assay

The ST88-14 and S462 cells were plated in serum-containing growth medium in 60 mm culture dishes at a seeding density of 5×10⁴ cells/dish. Cells were treated with carrier alone (0.1% DMSO) or flaccidoside II at the following gradient concentrations: 40.0 μmol L⁻¹, 20.0 μmol L⁻¹, 10.0 μmol L⁻¹, 5.0 μmol L⁻¹, and 2.50 μmol L⁻¹ for 24 hours or 48 hours. After incubation for designated times, apoptosis was assayed by using an Annexin V-PI staining kit by following the manufacturer’s procedure (KeyGen Biotechnology Co. Ltd., Nanjing, People’s Republic of China) as described earlier. The apoptotic rate was then detected by flow cytometry with the standardized program of the instrument (FACSCalibur; BD Biosciences, San Jose, CA, USA). Experiments were performed in four duplicates for each condition in each experiment, and a minimum of 500 cells was counted in each case. Assays were repeated three times independently.

Protein isolation and Western blotting

Protein extracts were prepared as previously described from MPNST cell lines ST88-14 and S462 growing in log phase in serum-containing growth medium. Cells were treated with 40.0 μmol L⁻¹ flaccidoside II for 48 hours. Nuclear and cytosolic fractions of proteins were obtained by a commercially available nuclear extraction kit (Panomics, Inc., Fremont, CA, USA). Then, cells were rinsed twice in ice-cold phosphate-buffered saline (pH 7.5), and cell lysates were prepared for Western blotting analysis by using whole cellular protein extraction kits (Santa Cruz Biotechnology Inc.). Protein concentration was determined using BCA kit (Pierce, Rockford, IL, USA). The cell lysate with certain amount of protein (20–50 μg) was first separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis gels and then electrically transferred to polyvinylidene difluoride membrane (EMD Millipore, Billerica, MA, USA). Detected proteins were incubated with specific antibodies overnight, immunoreactive bands were then visualized by an enhanced chemiluminescence plus detection kit (GE Biosciences, GE Healthcare Bio-Sciences, PA, USA) and exposed to CL-XPosure film. Protein bands were quantitatively analyzed by Kodak Digital Science 1D software (Eastman Kodak Company, New Haven, CT, USA) and were expressed as sum optical density.

HO enzyme activity assay

HO enzyme activity was determined as described previously. The reaction was carried out in the dark for 1 hour at 37°C then stopped by placing the tubes on dry ice, and bilirubin was extracted with chloroform. The amount of extracted bilirubin was estimated by the difference in absorbance between 463 nm and 520 nm by using a scanning spectrophotometer. The HO activity was calculated as pmol mg⁻¹ h⁻¹ and presented as fold change.

Statistical analysis

Statistical analysis among the various treatment groups in cell proliferation and apoptosis studies was performed by Prism (GraphPad Software, Inc., La Jolla, CA, USA). The one-way or two-way ANOVA procedure followed by least significant difference post hoc tests and Student’s t-test was used to determine the statistical significance of differences of the means. P<0.05 was considered statistically significant. The data were expressed as mean ± standard deviation (SD).

Results

Flaccidoside II inhibits proliferation and facilitates apoptosis in MPNST cell lines

First, we investigated the effect of triterpenoid saponin from the _A. flaccida_ on NF by performing flaccidoside II in NF1-related human MPNST cell lines ST88-14 and S462. The reason why we applied flaccidoside II here as a representative triterpenoid from compounds 1–5 is based on its “comprehensive” antitumor effect. We have assessed the antitumor effects of different triterpenoid saponins on several cancer cell models, including human BEL-7402 and HepG2 hepatoma cell lines, as well as the model of HeLa cells treated...
with lipopolysaccharide. According to our previous data, flaccidoside II has stronger antitumor effects comparing to other triterpenoid saponins in all the cell models we have measured.\textsuperscript{17} We measured the effect of flaccidoside II on MPNST cell proliferation by MTS assay. ST88-14 and S462 cells were treated with flaccidoside II at the following five gradient concentrations: 40.0 μmol L\(^{-1}\), 20.0 μmol L\(^{-1}\), 10.0 μmol L\(^{-1}\), 5.0 μmol L\(^{-1}\), and 2.50 μmol L\(^{-1}\) for 24 hours or 48 hours. As shown in Figure 1A and B, treatment of flaccidoside II at varying doses on ST88-14 and S462 cells showed that cytotoxicity induced by flaccidoside II was dose and time dependent with 90%–95% inhibition achieved at maximum concentration of 40.0 μmol L\(^{-1}\) after 48 hours of treatment.

We then characterized apoptosis of ST88-14 and S462 cells when treated with flaccidoside II that was demonstrated by Annexin V-FITC/PI flow cytometry assay. The results from ST88-14 and S462 cells are illustrated in Figure 2A and B, respectively. Consistent with the cell growth inhibition effect of flaccidoside II, the percentage of both early (18.7%) and late apoptotic cells (32.8%) for flaccidoside II treatment in ST88-14 and S462 cells significantly increased compared to controls. The apoptosis of ST88-14 and S462 cells induced by flaccidoside II was also confirmed by Western blotting measurements on the expression of cleaved PARP and cleaved caspase 3 at the gradient performance of flaccidoside II for 24 hours and 48 hours (Figure 2C–F). These data suggested that flaccidoside II inhibits proliferation in MPNST ST88-14 and S462 cells via inducing apoptosis.

**Flaccidoside II-mediated signal activates p38 MAPK and inhibits ERK-1/2 via phosphorylation**

To gain insight into the mechanism of action for flaccidoside II in MPNST tumorigenesis, we evaluated the MAPK signaling pathways. We and others have shown that triterpenoid saponins inhibit the COX-2/PGE2 pathway in cancer cells, which contribute their apoptotic effects, and the upstream MAPK-related inflammatory pathways play important roles for prevention and treatment of cancer by triterpenoids.\textsuperscript{34–36} Here, we wished to check whether flaccidoside II can modulate the activation of ERK-1/2, JNK, and p38 MAPK. The ST88-14 and S462 cells were treated with either 40.0 μmol L\(^{-1}\) flaccidoside II or DMSO for 48 hours. Following treatment, the phosphorylation statuses and total levels of p38, JNK, and ERK-1/2 were measured by Western blot. As shown in Figure 3A–C, the application of flaccidoside II increased the phosphorylation of p38 MAPK and reduced ERK-1/2 phosphorylation, while there were no significant changes in the phosphorylation of JNK, as well as the total levels of p38, JNK, and ERK-1/2 (Figure 3A–D). In addition, we found that the COX-2 protein expression level was markedly downregulated by flaccidoside II treatment, as shown in Figure 3A and E.

**Flaccidoside II-mediated signaling downregulates the expression and activation of antiapoptotic HO-1**

As shown in our previous work, flaccidoside II inhibits the COX-2/PGE2 pathway, which has key roles in the hallmarks

---

**Figure 1** Flaccidoside II inhibits proliferation in MPNST cell lines.

**Notes:** NF1-related human MPNST cell lines ST88-14 (**A**) and S462 (**B**) were treated with flaccidoside II at five gradient concentrations: 40.0 μmol L\(^{-1}\), 20.0 μmol L\(^{-1}\), 10.0 μmol L\(^{-1}\), 5.0 μmol L\(^{-1}\), and 2.50 μmol L\(^{-1}\) for 24 hours or 48 hours, respectively, and the dose-dependent antiproliferative effects were measured by MTT assay. *P<0.05, **P<0.01 vs control (mean ± SD). Each experiment was repeated at least three times, except specifically stated.

**Abbreviations:** MPNST, malignant peripheral nerve sheath tumor; NF1, neurofibromatosis type 1; SD, standard deviation.
Flaccidoside II triggers apoptosis via MAPK-HO-1 pathway

24 Serendipitously, we found in our experiment that HO-1 protein levels were markedly decreased in ST88-14 and S462 cells after treatment with flaccidoside II as shown in Figure 4A, and HO-1 has also shown to be inactivated by flaccidoside II (Figure 4B). In contrast, we also evaluated how the growth inhibitory functions of flaccidoside II can be affected if we overexpress
Figure 3 Flaccidoside II activates p38 MAPK and inhibits ERK-1/2 via phosphorylation, but not JNK pathway.

Notes: The ST88-14 and S462 cells were treated with either 40.0 μmol L⁻¹ flaccidoside II or DMSO for 48 hours, and the protein expression levels of phosphorylation and total p38 MAPK, ERK-1/2, and JNK as well as the protein expression level of COX-2 were measured by Western blotting, and β-actin was used as loading control (A). (B-E) Quantitative analyses of the blots in (A). Data represent the mean ± SD of four independent experiments. *P<0.05, **P<0.01, and ***P<0.001 vs control.

Abbreviations: MAPK, mitogen-activated protein kinase; ERK-1/2, extracellular signal-regulated kinase 1/2; JNK, c-Jun N-terminal kinase; DMSO, dimethyl sulfoxide; COX-2, cyclooxygenase-2; CON, control; fII, flaccidoside II; p-JNK, phosphor-JNK; SD, standard deviation.
Flaccidoside II triggers apoptosis via MAPK-HO-1 pathway

HO-1 in MPNST cells. We treated MPNST cells ST88-14 and S462 with flaccidoside II in the absence or presence of HO-1 overexpressed plasmid transfection and then compared the apoptotic rate of the transfected cells with nontransfected cells after 48 hours. The overexpression of HO-1 was confirmed by Western blotting (Figure 4C), and then the apoptosis of the cells was measured by flow cytometry and Western blotting of apoptosis marker PARP and caspase 3. As shown in Figure 4C–E, flaccidoside II increased apoptosis of ST88-14 and S462 cells; while flaccidoside II could not induce apoptosis with HO-1 overexpression up to the similar level as observed in nontransfected cells.

HO-1 downregulation induced by flaccidoside II is mediated by ERK-1/2 and p38 MAPK pathways

Several signaling pathways are reported to be involved in the regulation of HO-1, including PKC, PI3K/AKT, and...
Here, we investigated whether the upstream MAPK signaling pathway is involved in flaccidoside II-mediated HO-1 regulation, we next tested the effects of ERK-1/2 inhibitors PD98059 and p38 inhibitor SB203580 on HO-1 and MPNST apoptosis in the presence of flaccidoside II. Interestingly, we have found that the inhibitors alone did not change the apoptosis on basal level, while the application of ERK-1/2 inhibitors PD98059 further facilitated the apoptotic rate of ST88-14 and S462 cells with treatment of flaccidoside II; and it was reduced by p38 inhibitor SB203580 verified by Western blotting of apoptosis marker cleaved PARP and cleaved caspase 3 (Figure 5A–C). Meanwhile, PD98059 decreased the expression/activity of HO-1, while SB203580 increased them contrarily, although the effects were not significant when flaccidoside II was absent (Figure 5A, B, and D). These data suggested that ERK-1/2 and p38 MAPK pathways are involved in the downregulation of HO-1 mediated by flaccidoside II.

**Discussion**

The MPNSTs are aggressive, chemoresistant soft-tissue tumors with poor 5-year survival that arise in patients with NF1 or sporadically. By using NF1-related human MPNST cell lines, we sought to discover new compounds isolated from natural plants, which have potential therapeutic effects on MPNST by comparing the chemical structures with the data from an unbiased high-throughput chemical library screening approach (data not shown here). In this way, we found the promising compounds such as flaccidoside II, one of the triterpenoid saponins from *A. flaccida* Fr. Schmidt. Here, we performed cell proliferation assay and flow cytometry to confirm that flaccidoside II inhibits proliferation and facilitates apoptosis in NF1-associated MPNSTs cell lines ST88-14 and S462. Importantly, this is the first study to report that a compound from natural plants has antitumor capacity, which might represent a new insight for MPNST patient therapy.
The use of medicinal plants or their active components is becoming an increasingly attractive approach for the treatment of various inflammatory disorders and cancer. Flaccidoside II, as a bidesmosidic triterpene saponin isolated from Chinese folk medicine, has been synthesized and reported in previous research. However, very little is known about the function of flaccidoside II and its therapeutic potentials for human diseases. Resistance against apoptosis plays a central role in the cancer-supportive environment and provides significant rejection to the cytotoxicity of chemotherapy. Our previous work has revealed the anti-apoptotic role of flaccidoside II in cancer cell lines. In the present work, we investigated its effect on NF1-associated MPNSTs in the central and peripheral nervous systems. Combining our previous work with the data from high-throughput chemical library screening, it is not surprising to observe the roles on proliferation inhibition and apoptosis facilitation of flaccidoside II in MPNST cell lines, which could be due to its structure in which an L-rhamnopyranose links to other sugars at the end of glycosidic chain in C-3 position.

Furthermore, we define the mechanism by which flaccidoside II can mediate novel growth inhibitory signals in MPNST cells. Since we have reported in our previous work that the expression of COX-2 is inhibited by performing triterpenoid saponins, including flaccidoside II, and MAPK signaling pathways are known to be involved in the regulation of COX-2 expression, we sought to investigate whether MAPK signaling pathways participate in the underlying mechanisms of antiapoptotic role of flaccidoside II. We measured the activation and expression status of major MAPK family members, including ERK, p38, and JNK. Our data suggested that flaccidoside II activates p38 MAPK and inhibits ERK-1/2 via phosphorylation, while it has no significant effect on the phosphorylation of JNK and the total expression levels of ERK, p38, and JNK. Since MAP kinase signaling pathways represent a potential target for therapeutic intervention for cancers, here we revealed that flaccidoside II facilitates apoptosis in MPNSTs via regulating the activation of p38 MAPK and ERK-1/2, but not JNK pathway, which gave us a hint that flaccidoside II could be considered as a novel pharmacotherapeutic approach to MPNSTs based on its regulation of MAPK pathways.

HO-1 is one of the cytoprotective enzymes in response to various stimuli, including cellular oxidative stress and inflammation. HO-1 is highly induced in various disease states, including neurodegenerative diseases and cancer. Several lines of evidences have suggested the protective role of HO-1 in oxidative stress-induced neuronal injury and the expression of HO-1 may be regulated by oxidative stresses in a coordinated manner with tau, which plays a pivotal role in the cytoprotection of neuronal cells. However, in contrast, accumulating reports have supported that HO-1 participates in carcinogenesis and tumor progression by promoting proliferation and survival, inducing angiogenesis through regulating expression of angiogenic factors, and modulating tumor microenvironment as well. The protumorigenic role of HO-1 renders its potential as a molecular target for cancer therapy, while very little is known about the role of HO-1 on tumors in nervous system such as NF1-associated MPNSTs. In this study, we have shown that flaccidoside II downregulates the expression and the activation of HO-1, which is involved in the mechanisms of apoptotic facilitation of flaccidoside II. Furthermore, several reports demonstrated that p38-MAPK, ERK, PI3K, and PKC-δ are involved in HO-1 expression/activity. Signaling mechanisms involved in HO-1 induction may depend on cell types and inducers. Consistent with previous reports that MAPK pathways are important in modulating the HO-1 expression, we found in our experiments that ERK-1/2 and p38 MAPK pathways are upstream of HO-1 and involved in the downregulation of HO-1 mediated by flaccidoside II. Interestingly and importantly, we noticed in our experiments that the inhibitors alone did not change the HO-1 expression/activity on basal level, while the decrease in HO-1 expression/activity induced by flaccidoside II is regulated by ERK-1/2 and p38 MAPK inhibitors. These data strongly suggested the therapeutic potentials of ERK-1/2 and p38 MAPK pathways in HO-1 downregulation induced by flaccidoside II due to the specific effects at pathological state. There is no doubt that the in vivo verification of the phytotherapeutic potential of flaccidoside II on NF1-associated MPNSTs via the MAPK-HO-1 pathway such as in MPNST mouse model would be necessary in further research, although the MPNST cell lines ST88-14 and S462 are reliable for exploring the molecular mechanisms of the apoptotic effect of flaccidoside II.

Taken together, this study supports the view that flaccidoside II inhibits proliferation and facilitates apoptosis in NF1-associated MPNST cell lines, which renders its potential as a novel pharmacotherapeutic approach for MPNSTs. Furthermore, downregulation of HO-1 is required for the apoptotic role of flaccidoside II in MPNST cell lines ST88-14 and S462, and ERK-1/2 and p38 MAPK pathways are the upstream modulators for the process.
Acknowledgments

This research was funded by the National Natural Science Foundation of China (grant no 31000158), the National Science Foundation of Hubei Province of China (grant no 2013CFA040), and Wuhan Science and Technology Talent cultivation plan (grant no 2014070404010216).

Disclosure

The authors report no conflicts of interest in this work.

References

1. Goldberg NS, Collins FS. The hunt for the neurofibromatosis gene. Arch Dermatol. 1991;127(11):1705–1707.
2. Crawford AH, Schorry EK. Neurofibromatosis update. J Pediatr Orthop. 2006;26(3):413–425.
3. Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science. 1990;249(4965):181–186.
4. Lin AL, Gutmann DH. Advances in the treatment of neurofibromatosis-associated tumours. Nat Rev Clin Oncol. 2013;10(11):616–624.
5. Zwarthoff EC. Neurofibromatosis and associated tumour suppressor genes. Pathol Res Pract. 1996;192(7):647–657.
6. Zoller M, Rembeck B, Akesson HO, Angervall L. Life expectancy, major cancers, and life expectancy, major cancers, and life expectancy, major cancers, and life expectancy, major cancers, and life expectancy, major cancers. Br J Cancer. 1990;61(6):981–988.
7. Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science. 1990;249(4965):181–186.
8. Cichowski K, Shih TS, Schmitt E, et al. Mouse models of tumor growth and metastasis. Nat Rev Cancer. 2001;1(2):129–139.
9. Endo M, Kobayashi C, Setou N, et al. Progesterone-induced apoptosis of the human heme oxygenase gene. J Biochem. 2001;129(5):793–800.
10. Zwarthoff EC. Neurofibromatosis and associated tumour suppressor genes. Pathol Res Pract. 1996;192(7):647–657.
11. Zoller M, Rembeck B, Akesson HO, Angervall L. Life expectancy, major cancers, and life expectancy, major cancers, and life expectancy, major cancers, and life expectancy, major cancers. Br J Cancer. 1990;61(6):981–988.
12. Zoller M, Rembeck B, Akesson HO, Angervall L. Life expectancy, major cancers, and life expectancy, major cancers, and life expectancy, major cancers, and life expectancy, major cancers. Br J Cancer. 1990;61(6):981–988.
13. Zoller M, Rembeck B, Akesson HO, Angervall L. Life expectancy, major cancers, and life expectancy, major cancers, and life expectancy, major cancers, and life expectancy, major cancers. Br J Cancer. 1990;61(6):981–988.
14. Zoller M, Rembeck B, Akesson HO, Angervall L. Life expectancy, major cancers, and life expectancy, major cancers, and life expectancy, major cancers, and life expectancy, major cancers. Br J Cancer. 1990;61(6):981–988.
15. Zoller M, Rembeck B, Akesson HO, Angervall L. Life expectancy, major cancers, and life expectancy, major cancers, and life expectancy, major cancers, and life expectancy, major cancers. Br J Cancer. 1990;61(6):981–988.
16. Zoller M, Rembeck B, Akesson HO, Angervall L. Life expectancy, major cancers, and life expectancy, major cancers, and life expectancy, major cancers, and life expectancy, major cancers. Br J Cancer. 1990;61(6):981–988.
17. Zoller M, Rembeck B, Akesson HO, Angervall L. Life expectancy, major cancers, and life expectancy, major cancers, and life expectancy, major cancers, and life expectancy, major cancers. Br J Cancer. 1990;61(6):981–988.
18. Zoller M, Rembeck B, Akesson HO, Angervall L. Life expectancy, major cancers, and life expectancy, major cancers, and life expectancy, major cancers, and life expectancy, major cancers. Br J Cancer. 1990;61(6):981–988.
19. Zoller M, Rembeck B, Akesson HO, Angervall L. Life expectancy, major cancers, and life expectancy, major cancers, and life expectancy, major cancers, and life expectancy, major cancers. Br J Cancer. 1990;61(6):981–988.
20. Zoller M, Rembeck B, Akesson HO, Angervall L. Life expectancy, major cancers, and life expectancy, major cancers, and life expectancy, major cancers, and life expectancy, major cancers. Br J Cancer. 1990;61(6):981–988.
21. Tenhunen R, Marver HS, Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci U S A. 1968;61(2):748–755.
22. Pae HO, Jeong SO, Koo BS, Ha HY, Lee KM, Chung HT. Tranilast, an orally active anti-allergic drug, up-regulates the anti-inflammatory heme oxygenase-1 expression but down-regulates the pro-inflammatory cyclooxygenase-2 and inducible nitric oxide synthase expression in RAW264.7 macrophages. Biochem Biophys Res Commun. 2008;371(3):361–365.
23. Lee BW, Chun SW, Kim SH, et al. Lithospermic acid B protects beta-cells from cytokine-induced apoptosis by alleviating apoptotic pathways and activating anti-apoptotic pathways of Nrf2-HO-1 and Sirt1. Toxicol Appl Pharmacol. 2011;252(1):47–54.
24. Ryter SW, Alam J, Choi AM. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev. 2006;86(2):583–650.
25. Willis D, Moore AR, Frederick R, Willoughby DA. Heme oxygenase: a novel target for the modulation of the inflammatory response. Nat Med. 1996;2(1):87–90.
26. Jozkowicz A, Was H, Dulak J. Heme oxygenase-1 in tumors: is it a false friend? Antioxid Redox Signal. 2007;9(12):2099–2117.
27. Doi K, Akaike T, Fujii S, et al. Induction of haem oxygenase-1 nitric oxide and ischaemia in experimental solid tumours and implications for tumour growth. Br J Cancer. 1990;61(12):1945–1954.
28. Miller SJ, Rangwala F, Williams J, et al. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumour cell line and tissues. Cancer Res. 2006;66(5):2584–2591.
29. Johansson G, Mahller YY, Collins MH, et al. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumours. Mol Cancer Ther. 2008;7(5):1237–1245.
30. Liu XA, Liao K, Liu R, et al. Tau dephosphorylation potentiates apoptosis by mechanisms involving a failed dephosphorylation/activation of Bcl-2. J Alzheimers Dis. 2010;19(3):953–962.
31. Liu XA, Song J, Jiang Q, Wang Q, Tian Q, Wang JZ. Expression of the hyperphosphorylated tau attenuates ER stress-induced apoptosis with upregulation of unfolded protein response. Apoptosis. 2012;17(10):1039–1049.
32. Liu XA, Zhu LQ, Zhang Q, et al. Estradiol attenuates tau hyperphosphorylation induced by upregulation of protein kinase-A. Neurochem Res. 2008;33(9):1811–1820.
33. Abraham NG, Lavrsky V, Schwartzman ML, et al. Transfection of the human heme oxygenase gene into rabbit coronary microvessel endothelial cells: protective effect against heme and hemoglobin toxicity. Proc Natl Acad Sci U S A. 1995;92(15):6798–6802.
34. Leger DY, Liagre B, Beneytout JL. Role of MAPKs and NF-kappaB in diogenin-induced megakaryoctic differentiation and subsequent apoptosis in HEL cells. Int J Oncol. 2006;28(1):201–207.
35. Yadav VR, Prasad S, Sung B, Kannappan R, Aggarwal BB. Targeting inflammatory pathways by triterpenoids for prevention and treatment of cancer. Toxins (Basel). 2010;2(10):2428–2466.
36. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298(5600):1911–1912.
37. Ryter SW, Choi AM. Heme oxygenase-1: molecular mechanisms of gene expression in oxygen-related stress. Antioxid Redox Signal. 2002;4(4):625–632.
38. Bloom DA, Jaiswal AK. Phosphorylation of Nrf2 at Ser40 by protein kinase C in response to antioxidants leads to the release of Nrf2 from I? inductors, but is not required for Nrf2 stabilization/acclimation in the nucleus and transcriptional activation of antioxidant response element-mediated NAD(P)H:quinone oxidoreductase-1 gene expression. J Biol Chem. 2003;278(45):44675–44682.
39. Qi D, Ouyang C, Wang Y, et al. HO-1 attenuates hippocampal neurons injury via the activation of BDNF-TrkB-Pi3K/Akt signaling pathway in stroke. Brain Res. 2014;1577:69–76.
40. Nahimmy J, Livne-Bar I, Guo X, Sivak JM. ROS detoxification and profibrotic cytokines are linked by p38 MAPK signaling in a model of mature astrocite activation. PLoS ONE. 2013;8(12):e83049.
41. Cheng S, Du Y, Bing F, Zhang G. Synthesis of flaccidoside II, a bidemonic triterpene saponin isolated from Chinese folk medicine Di Wu. Carbohydr Res. 2008;343(3):462–469.
42. Merritt AJ, Potten CS, Watson AJ, Loh DY, Nakayama K, Hickman JA. Differential expression of bcl-2 in intestinal epithelia. Correlation with attenuation of apoptosis in colonic crypts and the incidence of colonic neoplasia. J Cell Sci. 1995;108(pt 6):2261–2271.
43. Huang F, Cao J, Liu Q, Zou Y, Li H, Yin T. MAPK/ERK signal pathway involved expression of COX-2 and VEGF by IL-1beta induced in human endometriosis stromal cells in vitro. Int J Clin Exp Pathol. 2013;6(10):2129–2136.
44. Lin CC, Hsieh HL, Shih RH, Chi PL, Cheng SE, Yang CM. Up-regulation of COX-2/PGE2 by endothelin-1 via MAPK-dependent NF-kappaB pathway in mouse brain microvascular endothelial cells. Cell Commun Signal. 2013;11(1):8.
45. Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002;12(1):9–18.
46. Le WD, Xie WJ, Appel SH. Protective role of heme oxygenase-1 in oxidative stress-induced neuronal injury. J Neurosci Res. 1999;56(6):652–658.
47. Takeda A, Perry G, Abraham NG, et al. Overexpression of heme oxygenase in neuronal cells, the possible interaction with Tau. J Biol Chem. 2000;275(8):5395–5399.
48. Chau LY. Heme oxygenase-1: emerging target of cancer therapy. J Biomed Sci. 2015;22:22.
49. Zhao M, Guo H, Chen J, et al. 5-aminolevulinic acid combined with sodium ferrous citrate ameliorates H2O2-induced cardiomyocyte hypertrophy via activation of the MAPK/Nrf2/HO-1 pathway. Am J Physiol Cell Physiol. 2015;308(8):C665–C672.
50. Kim JK, Jang HD. Nrf2-mediated HO-1 induction coupled with the ERK signaling pathway contributes to indirect antioxidant capacity of caffeic acid phenethyl ester in HepG2 cells. Int J Mol Sci. 2014;15(7):12149–12165.
51. Xu XH, Li GL, Wang BA, et al. Diallyl trisulfide protects against oxygen glucose deprivation-induced apoptosis by scavenging free radicals via the PI3K/Akt-mediated Nrf2/HO-1 signaling pathway in B35 neural cells. Brain Res. 2015;1614:38–50.
52. Lee SE, Jeong SI, Yang H, Park CS, Jin YH, Park YS. Fisetin induces Nrf2-mediated HO-1 expression through PKC-delta and p38 in human umbilical vein endothelial cells. J Cell Biochem. 2011;112(9):2352–2360.
53. Gong P, Cederbaum AI, Nieto N. Increased expression of cytochrome P450 2E1 induces heme oxygenase-1 through ERK MAPK pathway. J Biol Chem. 2003;278(32):29693–29700.